Germany-based pharma major Fresenius Kabii has broken ground on its $250m manufacturing campus in the Village of Melrose Park in Illinois, US.
The project will involve creation of several new buildings that will be connected to the existing manufacturing site, where Fresenius produces generic, sterile injectable pharmaceuticals used for chronically and critically ill patients.
The new campus will include automated aseptic filling lines and expanded lyophilisation (freeze-drying) capabilities, formulation areas, laboratories, cafeteria, a warehouse for raw materials, office space and an administration building with conference centre.
The project, expected to be wrapped up in 2026, will result in the creation of hundreds of manufacturing and construction jobs in the Melrose Park region.
Fresenius Kabi senior vice president of global operations for North America, pharmaceuticals division Steven Nowicki said: “This project will create many opportunities for our employees, who work around-the-clock to produce life-saving medicines for patients who need them.
"Our expectation is that the positive effects of this extensive construction project and our continued growth will benefit the people and business community of Melrose Park and Illinois."